Neurocentria Announces Dr. Thomas Südhof to Join the Scientific Advisory Board WALNUT CREEK, Calif., Jan. 13, 2023 (GLOBE NEWSWIRE) -- Neurocentria, Inc., a privately held late-stage biotechnology company developing novel therapies for neurodegenerative and neuropsychiatric...

Neurocentria Obtains FDA Approval to Conduct Pivotal Phase IIb/III Clinical Trial for Testing Safety and Efficacy of Drug Candidate NRCT-101SR in Adults With ADHD WALNUT CREEK, N.C., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Neurocentria Inc., a privately held late-stage biotechnology company developing novel therapies for Alzheimer's disease, Attention Deficit...